Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Terminated
• CT.gov ID: NCT01907815
• Collaborator: (none)
• Enrollment: 24
• Locations: 3
• Arm: 1
• Actual Duration (Months): 27
• Patients Per Site: 8
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This phase II trial studies how well trametinib and protein kinase B (Akt) inhibitor GSK2141795 work in treating patients with acute myeloid leukemia. Trametinib and Akt inhibitor GSK2141795 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia	Drug: Akt Inhibitor GSK2141795; Other: Laboratory Biomarker Analysis; Drug: Trametinib	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To determine the proportion of patients achieving complete remission (CR) or CR with incomplete recovery of platelets (CRp) as best response within 4 cycles of therapy of trametinib in combination with GSK2141795 (Akt inhibitor GSK2141795) in acute myeloid leukemia (AML) patients with rat sarcoma (RAS) mutations.

SECONDARY OBJECTIVES:

1. To determine the disease-free survival of patients achieving CR/CRp. II. To determine the duration of response of patients achieving CR/CRp. III. To determine the toxicity profile of trametinib in combination with GSK2141795 in this patient population.

2. To determine the biologic effects of trametinib in combination with GSK2141795 on leukemia cells.

OUTLINE:

Patients receive trametinib orally (PO) once daily (QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 12 weeks.

Study Design

• Study Type: Interventional
• Actual Enrollment: 24 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
• Actual Study Start Date: Oct 1, 2013
• Actual Primary Completion Date: Jan 1, 2016
• Actual Study Completion Date: Jan 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (trametinib, Akt inhibitor GSK2141795) Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Drug: Akt Inhibitor GSK2141795; Given PO; Other Names: GSK2141795 Oral Akt Inhibitor GSK2141795 ; Other: Laboratory Biomarker Analysis; Correlative studies; Drug: Trametinib; Given PO; Other Names: GSK1120212 JTP-74057 MEK Inhibitor GSK1120212 Mekinist

Outcome Measures

Primary Outcome Measures

1. Complete Response Rate (CRR, Defined as CR+CRp) Assessed by AML 2003 Response Criteria [First four cycles (16 weeks) of therapy, with evaluation after one full cycle of therapy (28 days) and up to 16 weeks for response]

   Proportion of participants achieving complete remission (CR) or CR with incomplete recovery of platelets (CRp) as best response within 4 cycles of therapy. Complete Response (CR): Disappearance all clinical &/or radiologic evidence of disease. Neutrophil count ≥ 1.0x10^9/L; Platelet count ≥ 100x109/L; Normal bone marrow differential (≤ 5% blasts); No extra-medullary leukemia. Complete Remission without Platelet Recovery (CRp): Peripheral blood & bone marrow results as for CR, but platelet counts of < 100x10^9/L. Partial Remission (PR): Blood count recovery as for CR, but decrease of at least 50% in % marrow blasts to >5% to 25% in bone marrow aspirate. Morphologic leukemia-free state: Normal marrow differential (<5% blasts); neutrophil & platelet counts not considered.95% confidence interval will be estimated for the combination regimen.

Secondary Outcome Measures

1. Most Frequently Reported Adverse Events (AE) [AE collected continuously over 28-day cycles and up to 28 days after last dose of study drug.]

   National Cancer Institute (NCI) published standardized definitions for adverse events (AEs), known as Common Terminology Criteria for Adverse Events (CTCAE), to describe the severity of organ toxicity for those receiving cancer therapy. Toxicity data is summarized by number of incidents experienced while participants were on study using most frequently reported AEs regardless of grade or relatedness as assessed by CTCAE version 4.0. Toxicity is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-threatening (Grade 4), with specific parameters according to the organ system involved. Death (Grade 5) is used for some of the criteria to denote a fatality. For full adverse event reporting see Adverse Event Section. Data collection over first four cycles (16 weeks) of therapy, with evaluation after full cycle of therapy (28 days), continuing AE collection until 28 days following last study drug dose.

2. Overall Survival of Participants Achieving CR/CRp [Up to 12 weeks]

   Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.

3. Progression Free Survival of Participants Achieving CR/CRp [Up to 12 weeks]

   Estimated disease-free survival period using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.

4. Time to Progression for Participants Achieving CR/CRp [Up to 12 weeks]

   Time to Progression (TTP) is defined as the length of time from the start of treatment to disease progression as measured in days for participants with complete response.

Other Outcome Measures

1. Maximum Percentage Change in Total and Phospho-proteins [Baseline to 12 weeks post therapy]

   Change in total and phospho-proteins assessed by densitometric quantitative data by western blot analysis, or mean fluorescent intensities by flow cytometry and will be assessed for each patient for all time points and graphically plotted for each dose level.

2. Percentage Change in Cellular Proteins [Baseline to day 28 post treatment]

   The 95% confidence interval will be assessed.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed AML, other than acute promyelocytic leukemia, as defined by the 2008 World Health Organization (WHO) criteria that have relapsed or refractory to standard chemotherapy; unsuitable for standard chemotherapy or unwilling to undergo standard chemotherapy; subjects >= 60 years of age with newly diagnosed AML who are not candidates for or have refused standard chemotherapy are eligible

• Patients with prior autologous and allogeneic hematopoietic stem cell transplantation are eligible if patients are off immunosuppression for > 1 month and have no evidence of active graft versus host disease (GVHD) except grade 1 skin GVHD

• Positive for RAS mutation (neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS] codon 12, 13, 61 mutation or Kirsten rat sarcoma viral oncogene homolog [KRAS] codon 12, 13, 61 mutation) at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory prior to study entry; mutational testing will be performed on bone marrow sample and/or peripheral blood; patients with previously known RAS mutations prior to study entry may be considered positive for RAS mutation for eligibility prior to a CLIA-certified laboratory confirmation of such a mutation at the discretion of the investigator; (appropriate blood and/or bone marrow samples must be taken for RAS determination and submitted to a CLIA-certified laboratory prior to study entry); however, if such a mutation is not confirmed by the M D Anderson Cancer Center (MDACC)/other center's CLIA-certified laboratory, the patient may be permitted to stay on the study if they wish and consent to do so but such patients' data will be analyzed separately

• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

• Life expectancy of greater than 4 weeks

• Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels

• All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 (except alopecia) prior to the first dose of the study drug

• Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (isolated total bilirubin > 1.5 institutional ULN is acceptable if bilirubin is fractionated and direct bilirubin is < 35%)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN

• Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 60 mL/min

• Fasting serum glucose =< 150 mg/dl (fasting is defined as at least 8 hours without oral intake)

• Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) AND at least 50%; LVEF can be assessed by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to randomization and agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• History of another malignancy; exception: patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible; consult the Cancer Therapy Evaluation Program (CTEP) Medical Monitor if unsure whether second malignancies meet the requirements specified above

• History of interstitial lung disease or pneumonitis

• Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to randomization; daily or weekly chemotherapy (with the exception of hydroxyurea) without the potential for delayed toxicity within 14 days prior to randomization unless there is evidence of rapidly progressive disease

• Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib/GSK2141795 and during the study

• Symptomatic or untreated leptomeningeal disease or brain metastases or spinal cord compression

• Patients with abnormal fasting glucose values (> 150 mg/dl) at screening will be excluded; in addition, patients with type 1 diabetes will also be excluded; however, patients with type 2 diabetes will be allowed if diagnosed >= 6 months prior to enrollment, and if presenting with regular hemoglobin A1C (HbA1C) =< 8% at screening

• Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO) or GSK2141795

• Current use of a prohibited medication; the following medications or non-drug therapies are prohibited:

• Other anti-cancer therapy while on study treatment; (Note: megestrol [Megace] if used as an appetite stimulant is allowed)

• Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis

• The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)

• Note: for proliferative disease, hydroxyurea will be allowed during weeks 1 and 2 of cycle 1 of study; hydroxyurea may be started or the dose changed during that 2-week period if it is clinically indicated; if a subject not previously on a stable dose of hydroxyurea needs to begin hydroxyurea or a subject on a stable dose needs to have their dose increased during the first 2 weeks, the investigator will notify the clinical team that this has been initiated

• Drugs that potently inhibit cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) should either be prohibited or used with caution; drugs which are strong inducers of cytochrome P450 family 3, subfamily A (CYP3A) should also be prohibited; drugs that are substrates of CYP3A4 or cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) with a narrow therapeutic index may be prohibited; drugs that are sensitive substrates of CYP3A4 or CYP2C8 should be used with caution; it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians' Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product

• History or current evidence/risk of retinal vein occlusion (RVO)

• History or evidence of cardiovascular risk including any of the following:

• LVEF < institutional LLN or < 50%

• A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec

• History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for > 30 days prior to randomization are eligible)

• History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for > 30 days prior to study dose are eligible)

• Patient with symptomatic bradycardia, or a history of clinically significant bradyarrhythmias such as sick sinus syndrome, second (2nd) degree atrioventricular (AV) block (Mobitz type 2)

• History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to study dose

• History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system

• Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy

• Patients with intra-cardiac defibrillators

• Known cardiac metastases

• Known active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection, are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications

• Any serious/and or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures

• The study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib/GSK2141795, the potential hazard to the fetus should be explained to the patient and partner (as applicable)

• HIV-positive patients on combination antiretroviral therapy are ineligible

• Hypoxia (oxygen saturation < 90% on room air) or in the opinion of the investigator any pulmonary compromise leading to hypoxia, at the time of study entry

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Chicago Comprehensive Cancer Center	Chicago	Illinois	United States	60637
2	University of Maryland/Greenebaum Cancer Center	Baltimore	Maryland	United States	21201
3	M D Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Nitin Jain, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: National Cancer Institute (NCI)
• ClinicalTrials.gov Identifier: NCT01907815
• Other Study ID Numbers: NCI-2013-01354; NCI-2013-01354; NCI 9443; 2013-0001; 9443; N01CM39; N01CM71; P30CA016672
• First Posted: Jul 25, 2013
• Last Update Posted: Apr 6, 2018
• Last Verified: Apr 1, 2018

• Additional relevant MeSH terms: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Trametinib

Study Results

Participant Flow

Recruitment Details	Recruitment Period: October 9, 2013 to January 25, 2016. All recruitment done within medical clinic settings at The University of Texas MD Anderson Cancer Center, The University of Chicago and The University of Maryland Greenebaum Cancer Center.
Pre-assignment Detail	Study was terminated early, stopped due to lack of efficacy.

Arm/Group Title	Trametinib 2.0 mg + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg orally once daily (PO QD) and Akt inhibitor GSK2141795 25 mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
Period Title: Overall Study
STARTED	17	7
COMPLETED	16	7
NOT COMPLETED	1	0

Baseline Characteristics

Arm/Group Title	Trametinib 2.0 mg + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg	Total
Arm/Group Description	Trametinib 2.0 mg PO QD + GSK2141795 25 mg PO QD on days 1-28.	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.	Total of all reporting groups
Overall Participants	17	7	24
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	68	69	69
Sex: Female, Male (Count of Participants)
Female	6 35.3%	3 42.9%	9 37.5%
Male	11 64.7%	4 57.1%	15 62.5%
Region of Enrollment (Count of Participants)
United States	17 100%	7 100%	24 100%

Outcome Measures

1. Primary Outcome

Title	Complete Response Rate (CRR, Defined as CR+CRp) Assessed by AML 2003 Response Criteria
Description	Proportion of participants achieving complete remission (CR) or CR with incomplete recovery of platelets (CRp) as best response within 4 cycles of therapy. Complete Response (CR): Disappearance all clinical &/or radiologic evidence of disease. Neutrophil count ≥ 1.0x10^9/L; Platelet count ≥ 100x109/L; Normal bone marrow differential (≤ 5% blasts); No extra-medullary leukemia. Complete Remission without Platelet Recovery (CRp): Peripheral blood & bone marrow results as for CR, but platelet counts of < 100x10^9/L. Partial Remission (PR): Blood count recovery as for CR, but decrease of at least 50% in % marrow blasts to >5% to 25% in bone marrow aspirate. Morphologic leukemia-free state: Normal marrow differential (<5% blasts); neutrophil & platelet counts not considered.95% confidence interval will be estimated for the combination regimen.
Time Frame	First four cycles (16 weeks) of therapy, with evaluation after one full cycle of therapy (28 days) and up to 16 weeks for response

Outcome Measure Data

Analysis Population Description

One participant in first cohort withdrew prior to treatment therefore excluded from study analysis.

Arm/Group Title	Trametinib 2.0 mg + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg PO QD & GSK2141795 25 mg PO QD on days 1-28.	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.
Measure Participants	16	7
Number [percentage of participants]	0 0%	0 0%

2. Secondary Outcome

Title	Most Frequently Reported Adverse Events (AE)
Description	National Cancer Institute (NCI) published standardized definitions for adverse events (AEs), known as Common Terminology Criteria for Adverse Events (CTCAE), to describe the severity of organ toxicity for those receiving cancer therapy. Toxicity data is summarized by number of incidents experienced while participants were on study using most frequently reported AEs regardless of grade or relatedness as assessed by CTCAE version 4.0. Toxicity is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-threatening (Grade 4), with specific parameters according to the organ system involved. Death (Grade 5) is used for some of the criteria to denote a fatality. For full adverse event reporting see Adverse Event Section. Data collection over first four cycles (16 weeks) of therapy, with evaluation after full cycle of therapy (28 days), continuing AE collection until 28 days following last study drug dose.
Time Frame	AE collected continuously over 28-day cycles and up to 28 days after last dose of study drug.

Outcome Measure Data

Analysis Population Description

One participant of the 17 registered in first cohort (Trametinib 2.0) withdrew without treatment and is excluded from adverse event reporting.

Arm/Group Title	Trametinib 2.0 + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg PO QD + GSK2141795 25 mg PO QD on days 1-28.	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.
Measure Participants	16	7
Anemia	15	3
Diarrhea	16	3
Fatigue	11	6
Fever	13	3
Nausea	8	3
Rash maculo-papular	6	5
Mucositis oral	5	3
Vomiting	7	1

3. Secondary Outcome

Title	Overall Survival of Participants Achieving CR/CRp
Description	Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.
Time Frame	Up to 12 weeks

Outcome Measure Data

Analysis Population Description

No participants achieved CR/CRp therefore analysis not available.

Arm/Group Title	Trametinib 2.0 mg + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg PO QD + GSK2141795 25 mg PO QD on days 1-28.	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.
Measure Participants	0	0

4. Secondary Outcome

Title	Progression Free Survival of Participants Achieving CR/CRp
Description	Estimated disease-free survival period using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.
Time Frame	Up to 12 weeks

Outcome Measure Data

Analysis Population Description

No participants achieved CR/CRp therefore analysis not available.

Arm/Group Title	Trametinib 2.0 mg + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg PO QD + GSK2141795 25 mg PO QD on days 1-28.	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.
Measure Participants	0	0

5. Secondary Outcome

Title	Time to Progression for Participants Achieving CR/CRp
Description	Time to Progression (TTP) is defined as the length of time from the start of treatment to disease progression as measured in days for participants with complete response.
Time Frame	Up to 12 weeks

Outcome Measure Data

Analysis Population Description

Outcome data were not collected and the Outcome will never be analyzed.

Arm/Group Title	Trametinib 2.0 + GSK2141795 25 mg	Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg PO QD + GSK2141795 25 mg PO QD on days 1-28.	Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.
Measure Participants	0	0

6. Other Pre-specified Outcome

Title	Maximum Percentage Change in Total and Phospho-proteins
Description	Change in total and phospho-proteins assessed by densitometric quantitative data by western blot analysis, or mean fluorescent intensities by flow cytometry and will be assessed for each patient for all time points and graphically plotted for each dose level.
Time Frame	Baseline to 12 weeks post therapy

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

7. Other Pre-specified Outcome

Title	Percentage Change in Cellular Proteins
Description	The 95% confidence interval will be assessed.
Time Frame	Baseline to day 28 post treatment

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

Adverse Events

Time Frame	Adverse events collected continuously over a 28-day cycle schedule and up to 28 days after last dose of study drug.
Adverse Event Reporting Description	One participant in first cohort withdrew prior to treatment therefore excluded from all study analysis.
Arm/Group Title	Trametinib 2.0 mg + GSK2141795 25 mg		Trametinib 1.5 mg + GSK2141795 50 mg
Arm/Group Description	Trametinib 2.0 mg PO QD + GSK2141795 25 mg PO QD on days 1-28.		Trametinib 1.5 mg PO QD + GSK2141795 50 mg PO QD on days 1-28.
All Cause Mortality
	Trametinib 2.0 mg + GSK2141795 25 mg		Trametinib 1.5 mg + GSK2141795 50 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Trametinib 2.0 mg + GSK2141795 25 mg		Trametinib 1.5 mg + GSK2141795 50 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/16 (68.8%)		6/7 (85.7%)
Blood and lymphatic system disorders
Febrile neutropenia	1/16 (6.3%)	2	1/7 (14.3%)	1
Leukocytosis	1/16 (6.3%)	1	0/7 (0%)	0
Cardiac disorders
Atrial fibrillation	0/16 (0%)	0	1/7 (14.3%)	1
Carotid Stent placed	1/16 (6.3%)	1	0/7 (0%)	0
Myocardial infarction	1/16 (6.3%)	1	0/7 (0%)	0
Gastrointestinal disorders
Diarrhea	2/16 (12.5%)	2	0/7 (0%)	0
Gastric hemorrhage	1/16 (6.3%)	1	0/7 (0%)	0
Gastric perforation	0/16 (0%)	0	1/7 (14.3%)	1
Lower gastrointestinal hemorrhage Gastric Ulcer	0/16 (0%)	0	1/7 (14.3%)	1
Mucositis oral	0/16 (0%)	0	1/7 (14.3%)	1
Nausea	1/16 (6.3%)	1	0/7 (0%)	0
Rectal pain	1/16 (6.3%)	1	0/7 (0%)	0
Vomiting	1/16 (6.3%)	1	0/7 (0%)	0
General disorders
Death NOS	3/16 (18.8%)	3	0/7 (0%)	0
Fever	2/16 (12.5%)	5	0/7 (0%)	0
Infections and infestations
Catheter related infection	0/16 (0%)	0	1/7 (14.3%)	1
Lung infection	1/16 (6.3%)	1	0/7 (0%)	0
Sepsis	1/16 (6.3%)	1	2/7 (28.6%)	2
Injury, poisoning and procedural complications
Fall	1/16 (6.3%)	1	0/7 (0%)	0
Investigations
Alanine aminotransferase increased	1/16 (6.3%)	1	0/7 (0%)	0
Alkaline phosphatase increased	1/16 (6.3%)	1	0/7 (0%)	0
Creatinine increased	0/16 (0%)	0	1/7 (14.3%)	1
Ejection fraction decreased	1/16 (6.3%)	1	1/7 (14.3%)	1
Metabolism and nutrition disorders
Dehydration	1/16 (6.3%)	1	1/7 (14.3%)	1
Tumor lysis syndrome	0/16 (0%)	0	1/7 (14.3%)	1
Nervous system disorders
Syncope	1/16 (6.3%)	1	0/7 (0%)	0
Psychiatric disorders
Confusion	1/16 (6.3%)	1	0/7 (0%)	0
Reproductive system and breast disorders
Dyspnea	2/16 (12.5%)	2	1/7 (14.3%)	1
Respiratory, thoracic and mediastinal disorders
Bronchial infection	0/16 (0%)	0	1/7 (14.3%)	1
Bronchopulmonary hemorrhage	0/16 (0%)	0	1/7 (14.3%)	1
Skin and subcutaneous tissue disorders
Rash maculo-papular	0/16 (0%)	0	1/7 (14.3%)	1
Skin infection	1/16 (6.3%)	1	0/7 (0%)	0
Vascular disorders
Hypotension	3/16 (18.8%)	4	0/7 (0%)	0
Other (Not Including Serious) Adverse Events
	Trametinib 2.0 mg + GSK2141795 25 mg		Trametinib 1.5 mg + GSK2141795 50 mg
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	16/16 (100%)		6/7 (85.7%)
Blood and lymphatic system disorders
Anemia	5/16 (31.3%)	15	2/7 (28.6%)	3
Febrile neutropenia	4/16 (25%)	5	1/7 (14.3%)	1
Leukocytosis	1/16 (6.3%)	1	0/7 (0%)	0
Thrombotic thrombocytopenic purpura	0/16 (0%)	0	3/7 (42.9%)	4
Cardiac disorders
Acute coronary syndrome	1/16 (6.3%)	1	1/7 (14.3%)	1
Atrial fibrillation	0/16 (0%)	0	2/7 (28.6%)	4
Cardiac arrest	0/16 (0%)	0	2/7 (28.6%)	2
Cardiac disorders - Carotid Stent placed	1/16 (6.3%)	1	0/7 (0%)	0
Chest pain - cardiac	1/16 (6.3%)	2	0/7 (0%)	0
Myocardial infarction	1/16 (6.3%)	1	0/7 (0%)	0
Ear and labyrinth disorders
External ear inflammation	0/16 (0%)	0	1/7 (14.3%)	1
Endocrine disorders
Hypothyroidism	0/16 (0%)	0	1/7 (14.3%)	1
Eye disorders
Eye disorders - (Other)	2/16 (12.5%)	2	0/7 (0%)	0
Eye infection	0/16 (0%)	0	1/7 (14.3%)	1
Eye pain	0/16 (0%)	0	1/7 (14.3%)	2
Eyelid function disorder	0/16 (0%)	0	1/7 (14.3%)	1
Gastrointestinal disorders
Abdominal pain	3/16 (18.8%)	3	1/7 (14.3%)	1
Colitis	0/16 (0%)	0	1/7 (14.3%)	1
Constipation	1/16 (6.3%)	1	1/7 (14.3%)	1
Diarrhea	10/16 (62.5%)	14	3/7 (42.9%)	3
Dyspepsia	2/16 (12.5%)	2	0/7 (0%)	0
Esophageal necrosis	1/16 (6.3%)	1	0/7 (0%)	0
Gastric hemorrhage	1/16 (6.3%)	1	0/7 (0%)	0
Gastric perforation	0/16 (0%)	0	1/7 (14.3%)	1
Gastric ulcer	1/16 (6.3%)	1	0/7 (0%)	0
Gastroesophageal reflux disease	1/16 (6.3%)	1	0/7 (0%)	0
Ileus	1/16 (6.3%)	1	0/7 (0%)	0
Lower gastrointestinal hemorrhage Gastric Ulcer	0/16 (0%)	0	1/7 (14.3%)	1
Mucositis oral	4/16 (25%)	5	1/7 (14.3%)	2
Nausea	6/16 (37.5%)	7	3/7 (42.9%)	3
Oral pain	1/16 (6.3%)	1	0/7 (0%)	0
Rectal pain	1/16 (6.3%)	1	0/7 (0%)	0
Upper gastrointestinal hemorrhage	1/16 (6.3%)	1	0/7 (0%)	0
Vomiting	5/16 (31.3%)	6	1/7 (14.3%)	1
General disorders
Edema limbs	2/16 (12.5%)	2	1/7 (14.3%)	1
Fatigue	8/16 (50%)	11	5/7 (71.4%)	6
Fever	5/16 (31.3%)	8	3/7 (42.9%)	3
Gait disturbance	0/16 (0%)	0	1/7 (14.3%)	1
General disorders and administration site conditions - (Other)	1/16 (6.3%)	1	0/7 (0%)	0
Lymphocyte count decreased	3/16 (18.8%)	3	0/7 (0%)	0
Malaise	0/16 (0%)	0	3/7 (42.9%)	3
Pain	2/16 (12.5%)	2	2/7 (28.6%)	2
Hepatobiliary disorders
Cholecystitis	1/16 (6.3%)	3	0/7 (0%)	0
Infections and infestations
Catheter related infection	0/16 (0%)	0	1/7 (14.3%)	1
Infections and infestations - (Other)	2/16 (12.5%)	3	0/7 (0%)	0
Lung infection	2/16 (12.5%)	2	0/7 (0%)	0
Sepsis	1/16 (6.3%)	1	2/7 (28.6%)	2
Wound infection	1/16 (6.3%)	1	1/7 (14.3%)	1
Injury, poisoning and procedural complications
Fall	1/16 (6.3%)	1	0/7 (0%)	0
Injury, poisoning and procedural complications - (Other)	1/16 (6.3%)	1	0/7 (0%)	0
Investigations
Alanine aminotransferase increased	4/16 (25%)	4	0/7 (0%)	0
Alkaline phosphatase increased	3/16 (18.8%)	3	0/7 (0%)	0
Aspartate aminotransferase increased	3/16 (18.8%)	4	0/7 (0%)	0
Creatinine increased	1/16 (6.3%)	1	1/7 (14.3%)	1
Ejection fraction decreased	0/16 (0%)	0	1/7 (14.3%)	1
INR increased	1/16 (6.3%)	1	0/7 (0%)	0
Neutrophil count decreased	3/16 (18.8%)	3	1/7 (14.3%)	1
Platelet count decreased	4/16 (25%)	4	0/7 (0%)	0
Weight loss	2/16 (12.5%)	2	0/7 (0%)	0
White blood cell decreased	3/16 (18.8%)	5	1/7 (14.3%)	1
Metabolism and nutrition disorders
Anorexia	3/16 (18.8%)	3	2/7 (28.6%)	2
Dehydration	1/16 (6.3%)	1	2/7 (28.6%)	2
Hypermagnesemia	1/16 (6.3%)	1	0/7 (0%)	0
Hyperuricemia	3/16 (18.8%)	3	1/7 (14.3%)	1
Hypoalbuminemia	3/16 (18.8%)	5	0/7 (0%)	0
Hypocalcemia	3/16 (18.8%)	3	0/7 (0%)	0
Hypokalemia	1/16 (6.3%)	1	1/7 (14.3%)	2
Hypomagnesemia	4/16 (25%)	4	2/7 (28.6%)	2
Hyponatremia	2/16 (12.5%)	2	0/7 (0%)	0
Hypophosphatemia	1/16 (6.3%)	1	1/7 (14.3%)	1
Iron overload	0/16 (0%)	0	1/7 (14.3%)	1
Tumor lysis syndrome	0/16 (0%)	0	1/7 (14.3%)	1
Musculoskeletal and connective tissue disorders
Arthritis	1/16 (6.3%)	1	0/7 (0%)	0
Back pain	1/16 (6.3%)	1	0/7 (0%)	0
Bone pain	0/16 (0%)	0	1/7 (14.3%)	1
Joint range of motion decreased	0/16 (0%)	0	1/7 (14.3%)	1
Muscle weakness upper limb	1/16 (6.3%)	1	0/7 (0%)	0
Pain in extremity	1/16 (6.3%)	1	2/7 (28.6%)	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - (Other)	2/16 (12.5%)	2	0/7 (0%)	0
Nervous system disorders
Dizziness	1/16 (6.3%)	1	2/7 (28.6%)	2
Dysgeusia	1/16 (6.3%)	1	0/7 (0%)	0
Headache	0/16 (0%)	0	1/7 (14.3%)	1
Seizure	1/16 (6.3%)	1	0/7 (0%)	0
Syncope	1/16 (6.3%)	1	0/7 (0%)	0
Psychiatric disorders
Anxiety	1/16 (6.3%)	1	0/7 (0%)	0
Confusion	2/16 (12.5%)	2	0/7 (0%)	0
Delirium	1/16 (6.3%)	1	0/7 (0%)	0
Depression	0/16 (0%)	0	1/7 (14.3%)	1
Renal and urinary disorders
Acute kidney injury	2/16 (12.5%)	3	1/7 (14.3%)	3
Chronic kidney disease	0/16 (0%)	0	1/7 (14.3%)	1
Hematuria	1/16 (6.3%)	1	0/7 (0%)	0
Renal and urinary disorders - (Other)	1/16 (6.3%)	1	1/7 (14.3%)	1
Urinary tract pain	0/16 (0%)	0	1/7 (14.3%)	1
Reproductive system and breast disorders
Dyspnea	3/16 (18.8%)	3	2/7 (28.6%)	2
Hot flashes	0/16 (0%)	0	1/7 (14.3%)	1
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis	1/16 (6.3%)	1	0/7 (0%)	0
Aspiration	1/16 (6.3%)	1	0/7 (0%)	0
Bronchial infection	1/16 (6.3%)	1	1/7 (14.3%)	1
Bronchopulmonary hemorrhage	0/16 (0%)	0	1/7 (14.3%)	1
Cough	0/16 (0%)	0	2/7 (28.6%)	2
Epistaxis	1/16 (6.3%)	1	3/7 (42.9%)	3
Nasal congestion	1/16 (6.3%)	1	0/7 (0%)	0
Pleural effusion	1/16 (6.3%)	1	1/7 (14.3%)	1
Pneumonitis	0/16 (0%)	0	1/7 (14.3%)	1
Sore throat	2/16 (12.5%)	2	0/7 (0%)	0
Skin and subcutaneous tissue disorders
Pruritus	1/16 (6.3%)	1	0/7 (0%)	0
Purpura	1/16 (6.3%)	1	0/7 (0%)	0
Rash acneiform	1/16 (6.3%)	2	0/7 (0%)	0
Rash maculo-papular	5/16 (31.3%)	6	3/7 (42.9%)	4
Skin infection	1/16 (6.3%)	1	0/7 (0%)	0
Vascular disorders
Hypertension	2/16 (12.5%)	3	0/7 (0%)	0
Hypotension	3/16 (18.8%)	4	1/7 (14.3%)	1
Thromboembolic event	2/16 (12.5%)	2	0/7 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.